Ultima-AOD9604 2mg

MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE Anti-Obesity Drug-9604 ,

Products are being shipped without brand labeling for security purposes.

AOD 9604 is a modified version of Growth Hormone consisting of a peptide made up of 191 amino acids. It specifically reproduces the last 15 amino acids (176-191) of the Growth Hormone polypeptide, and is thus referred to as GH Frag 176-191 or AOD 9604.

AOD 9604 is regarded as one of the most effective peptides for weight loss, offering additional advantages such as improved fat reduction and enhanced metabolism.

Pituitary Gland

- Reduces body fat - Prompts fat release from obese fat cells more effectively than from lean ones - Mimics how natural growth hormone manages fat metabolism - Does not negatively affect blood sugar levels or growth - Stimulates lipolysis - Inhibits lipogenesis, the process of converting non-fatty foods into body fat - Demonstrates favorable effects on cartilage repair and regeneration, especially in conjunction with peptide BPC 157.

AOD-9604, also known as Tyr-hGH Frag 176-191, has been shown to possess significant fat-burning capabilities without promoting overeating. It does not impact blood sugar levels or tissue growth. AOD-9604 activates fat degradation and oxidation through a mechanism that does not involve hGH receptors, operating independently of hGH. Research involving rodents, pigs, dogs, and humans has revealed that AOD-9604 triggers the release of fat from predominantly obese fat cells, reduces the accumulation of new fat, and enhances fat burning. Notably, AOD-9604 is particularly effective in decreasing abdominal fat.

The second most potent fat loss peptide is CJC-1295, which increases overall GH levels in the body, countering the natural decline of GH as individuals age. This is significant as it helps explain why many people tend to gain weight as they grow older. For those focused solely on fat loss, it’s advisable to avoid GHRPs (such as GHRP-6, GHRP-2, or GHRH), as they can induce increased hunger and elevated cortisol levels. In contrast, AOD-9604 does not lead to increased hunger or heightened cortisol.

AOD-9604 (Advanced Obesity Drug) was developed in the 1990s by Professor Frank Ng at Monash University in Australia, aiming to create an anti-obesity treatment with the fat-burning benefits of human growth hormone (HGH) without the muscle-building effects.

Recent studies have revealed that AOD 9604 not only aids in fat loss but also possesses several regenerative properties linked to growth hormone. Ongoing trials are exploring the use of AOD 9604 for osteoarthritis, hypercholesterolemia, and the repair of bone and cartilage.

Results from oral glucose tolerance tests indicated that, unlike HGH, AOD 9604 does not adversely affect carbohydrate metabolism. No anti-AOD 9604 antibodies were found in any of the patients evaluated for this assay. There were no reports of withdrawal or serious adverse events related to the use of AOD 9604 in any of the studies.

AOD 9604 has shown an excellent safety and tolerability profile, similar to that of a placebo. It does not produce side effects associated with full-length hGH treatments. AOD 9604 boasts a great safety record and recently received Human GRAS status in the USA.